Pharmacologic Therapy for Type 2 Diabetes: Synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes

James J. Chamberlain, William H. Herman, Sandra Leal, Andrew S. Rhinehart, Jay H. Shubrook, Neil Skolnik, Rita R. Kalyani

Research output: Contribution to journalArticle

Abstract

Description: The American Diabetes Association (ADA) annually updates the Standards of Medical Care in Diabetes to provide clinicians, patients, researchers, payers, and other interested parties with evidence-based recommendations for the diagnosis and management of patients with diabetes.

Methods: For the 2017 Standards, the ADA Professional Practice Committee updated previous MEDLINE searches performed from 1 January 2016 to November 2016 to add, clarify, or revise recommendations based on new evidence. The committee rates the recommendations as A, B, or C, depending on the quality of evidence, or E for expert consensus or clinical experience. The Standards were reviewed and approved by the Executive Committee of the ADA Board of Directors, which includes health care professionals, scientists, and laypersons. Feedback from the larger clinical community informed revisions.

Recommendations: This synopsis focuses on recommendations from the 2017 Standards about pharmacologic approaches to glycemic treatment of type 2 diabetes.

Original languageEnglish (US)
Pages (from-to)572-578
Number of pages7
JournalAnnals of Internal Medicine
Volume166
Issue number8
DOIs
StatePublished - Apr 18 2017

Fingerprint

Standard of Care
Type 2 Diabetes Mellitus
Professional Practice
MEDLINE
Therapeutics
Research Personnel
Delivery of Health Care

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Pharmacologic Therapy for Type 2 Diabetes : Synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes. / Chamberlain, James J.; Herman, William H.; Leal, Sandra; Rhinehart, Andrew S.; Shubrook, Jay H.; Skolnik, Neil; Kalyani, Rita R.

In: Annals of Internal Medicine, Vol. 166, No. 8, 18.04.2017, p. 572-578.

Research output: Contribution to journalArticle

Chamberlain, James J. ; Herman, William H. ; Leal, Sandra ; Rhinehart, Andrew S. ; Shubrook, Jay H. ; Skolnik, Neil ; Kalyani, Rita R. / Pharmacologic Therapy for Type 2 Diabetes : Synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes. In: Annals of Internal Medicine. 2017 ; Vol. 166, No. 8. pp. 572-578.
@article{125f3a1ef29140fd933c63faff2ee3ef,
title = "Pharmacologic Therapy for Type 2 Diabetes: Synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes",
abstract = "Description: The American Diabetes Association (ADA) annually updates the Standards of Medical Care in Diabetes to provide clinicians, patients, researchers, payers, and other interested parties with evidence-based recommendations for the diagnosis and management of patients with diabetes.Methods: For the 2017 Standards, the ADA Professional Practice Committee updated previous MEDLINE searches performed from 1 January 2016 to November 2016 to add, clarify, or revise recommendations based on new evidence. The committee rates the recommendations as A, B, or C, depending on the quality of evidence, or E for expert consensus or clinical experience. The Standards were reviewed and approved by the Executive Committee of the ADA Board of Directors, which includes health care professionals, scientists, and laypersons. Feedback from the larger clinical community informed revisions.Recommendations: This synopsis focuses on recommendations from the 2017 Standards about pharmacologic approaches to glycemic treatment of type 2 diabetes.",
author = "Chamberlain, {James J.} and Herman, {William H.} and Sandra Leal and Rhinehart, {Andrew S.} and Shubrook, {Jay H.} and Neil Skolnik and Kalyani, {Rita R.}",
year = "2017",
month = "4",
day = "18",
doi = "10.7326/M16-2937",
language = "English (US)",
volume = "166",
pages = "572--578",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "8",

}

TY - JOUR

T1 - Pharmacologic Therapy for Type 2 Diabetes

T2 - Synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes

AU - Chamberlain, James J.

AU - Herman, William H.

AU - Leal, Sandra

AU - Rhinehart, Andrew S.

AU - Shubrook, Jay H.

AU - Skolnik, Neil

AU - Kalyani, Rita R.

PY - 2017/4/18

Y1 - 2017/4/18

N2 - Description: The American Diabetes Association (ADA) annually updates the Standards of Medical Care in Diabetes to provide clinicians, patients, researchers, payers, and other interested parties with evidence-based recommendations for the diagnosis and management of patients with diabetes.Methods: For the 2017 Standards, the ADA Professional Practice Committee updated previous MEDLINE searches performed from 1 January 2016 to November 2016 to add, clarify, or revise recommendations based on new evidence. The committee rates the recommendations as A, B, or C, depending on the quality of evidence, or E for expert consensus or clinical experience. The Standards were reviewed and approved by the Executive Committee of the ADA Board of Directors, which includes health care professionals, scientists, and laypersons. Feedback from the larger clinical community informed revisions.Recommendations: This synopsis focuses on recommendations from the 2017 Standards about pharmacologic approaches to glycemic treatment of type 2 diabetes.

AB - Description: The American Diabetes Association (ADA) annually updates the Standards of Medical Care in Diabetes to provide clinicians, patients, researchers, payers, and other interested parties with evidence-based recommendations for the diagnosis and management of patients with diabetes.Methods: For the 2017 Standards, the ADA Professional Practice Committee updated previous MEDLINE searches performed from 1 January 2016 to November 2016 to add, clarify, or revise recommendations based on new evidence. The committee rates the recommendations as A, B, or C, depending on the quality of evidence, or E for expert consensus or clinical experience. The Standards were reviewed and approved by the Executive Committee of the ADA Board of Directors, which includes health care professionals, scientists, and laypersons. Feedback from the larger clinical community informed revisions.Recommendations: This synopsis focuses on recommendations from the 2017 Standards about pharmacologic approaches to glycemic treatment of type 2 diabetes.

UR - http://www.scopus.com/inward/record.url?scp=85021389331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021389331&partnerID=8YFLogxK

U2 - 10.7326/M16-2937

DO - 10.7326/M16-2937

M3 - Article

C2 - 28288484

AN - SCOPUS:85021389331

VL - 166

SP - 572

EP - 578

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 8

ER -